Education
About Us
Working with TipRanks
Follow Us
Lucid Diagnostics Inc. (LUCD)
NASDAQ:LUCD
LUCD Stock Chart & Stats
$1.19
>-$0.01(-1.09%)
At close: 4:00 PM EST
$1.19
>-$0.01(-1.09%)
Day’s Range― - ―
52-Week Range$0.89 - $1.80
Previous CloseN/A
Volume130.18K
Average Volume (3M)1.75M
Market Cap
$156.01M
Enterprise Value$98.10M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.03
Next Earnings
Mar 30, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding131,098,750
10 Day Avg. Volume4,407,933
30 Day Avg. Volume1,752,964
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)7.67
Price to Sales (P/S)9.52
P/FCF Ratio-0.92
Enterprise Value/Market Cap0.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4.05Price Target Upside240.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial Position And Commercialization ReadinessA cash balance of about $47 million against $22 million of debt provides runway into 2027, supporting planned commercialization acceleration and ongoing discussions with commercial payors to expand private coverage.
Market Opportunity And DemandAn estimated U.S. addressable market of approximately $2 billion, combined with sequential increases in average selling price and test volumes, indicates meaningful revenue upside if clinical adoption expands.
Regulatory And Medicare CoverageUnanimous expert support from a Contractor Advisory Committee increases the likelihood that Centers for Medicare & Medicaid Services will revise Local Coverage Determination to include EsoGuard, enabling reimbursement and a one-year look-back for claims that could accelerate adoption.
Bears Say
Profitability PressureContinued GAAP losses, even if slightly narrower than expected, underscore ongoing profitability pressure until material top-line growth is achieved.
Revenue PerformanceReported revenue below consensus points to difficulty scaling sales and increases the risk of downward revisions to revenue forecasts.
Lucid Diagnostics News
LUCD FAQ
What was Lucid Diagnostics Inc.’s price range in the past 12 months?
Lucid Diagnostics Inc. lowest stock price was $0.89 and its highest was $1.80 in the past 12 months.
What is Lucid Diagnostics Inc.’s market cap?
Lucid Diagnostics Inc.’s market cap is $156.01M.
When is Lucid Diagnostics Inc.’s upcoming earnings report date?
Lucid Diagnostics Inc.’s upcoming earnings report date is Mar 30, 2026 which is in 56 days.
How were Lucid Diagnostics Inc.’s earnings last quarter?
Lucid Diagnostics Inc. released its earnings results on Nov 12, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.095 by -$0.005.
Is Lucid Diagnostics Inc. overvalued?
According to Wall Street analysts Lucid Diagnostics Inc.’s price is currently Undervalued.
Does Lucid Diagnostics Inc. pay dividends?
Lucid Diagnostics Inc. does not currently pay dividends.
What is Lucid Diagnostics Inc.’s EPS estimate?
Lucid Diagnostics Inc.’s EPS estimate is -0.09.
How many shares outstanding does Lucid Diagnostics Inc. have?
Lucid Diagnostics Inc. has 131,098,750 shares outstanding.
What happened to Lucid Diagnostics Inc.’s price movement after its last earnings report?
Lucid Diagnostics Inc. reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.095. Following the earnings report the stock price went up 6.731%.
Which hedge fund is a major shareholder of Lucid Diagnostics Inc.?
Currently, no hedge funds are holding shares in LUCD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lucid Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.05 (240.34% Upside)
$4.05 (240.34% Upside)
Blogger Sentiment
Bullish
LUCD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 29.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.92%
12-Months-Change
Fundamentals
Return on Equity
-331.24%
Trailing 12-Months
Asset Growth
135.41%
Trailing 12-Months
Company Description
Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
LUCD Company Deck
LUCD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant strategic achievements, including strengthening the market access team and positive progress towards Medicare coverage, which are expected to drive future growth. However, the company faced flat revenue growth and ongoing reimbursement challenges, impacting short-term financial performance.View all LUCD earnings summariesLUCD Stock 12 Month Forecast
Average Price Target
$4.05
▲(240.34% Upside)
Technical Analysis
Ownership Overview
2.52% Insiders
4.46% Mutual Funds
0.02% Other Institutional Investors
87.65% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---